Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
Tag Archive for: adeno-associated virus (AAV) vector
Topline data from Lysogene’s Phase II/III AAVance study showed its investigational gene therapy, LYS-SAF302, failed to meet its primary and key secondary efficacy endpoints in mucopolysaccharidosis type IIIA.
